Type II alveolar epithelial cell apoptosis

"Type II alveolar epithelial cell apoptosis" describes a process, not a discrete molecular entity or traditional drug target. Type II alveolar epithelial cells (also called AT2, AE2, or AECII) are specialized lung cells responsible for surfactant production, alveolar maintenance, regeneration after injury, and innate immunity[1][3][4][6]. Apoptosis (programmed cell death) of these cells plays a central role in the pathogenesis of several lung diseases, especially idiopathic pulmonary fibrosis (IPF) and other forms of pulmonary fibrosis[2][7]. Loss or dysfunction of AT2 cells through apoptosis disrupts alveolar homeostasis, limits regeneration capacity, leads to surfactant deficiency, and can provoke inflammatory and fibrotic responses through interactions with alveolar macrophages and signaling pathways such as TGF-β[1][2][7]. While prevention or modulation of AT2 apoptosis is being explored for therapeutic benefit, "Type II alveolar epithelial cell apoptosis" itself is not a molecule or receptor, but rather a critical pathological process—so it is not a therapeutic target in the conventional, molecular sense[2][7].

Other names

Alveolar epithelial type II cell apoptosisAT2 cell apoptosisAECII apoptosis